N-Acetyl-S-farnesyl-L-cysteine
S-Farnesylcystine methyl transferase inhibitor / N-Acetyl-S-farnesyl-L-cysteine (AFC) inhibits S-farnesylcysteine methyl transferase (Km = 20 µM).1 AFC blocked capacitative Ca2+ influx in human embryonic kidney 293 cells2 and store-regulated Ca2+ entry in human platelets3. Topical AFC has been shown to inhibit neutrophil chemotaxis and other inflammatory responses without systemic effects.4,5
Biochemicals & reagents
135304-07-3
AFC
1) Volker et al. (1991), Effects of farnesylcyteine analogs on protein carboxyl methylation and signal tranduction; J.Biol.Chem. 266 21515 2) Xu et al. (1996), Inhibition of capacitative Ca2+ entry into cells by farnesyl analogs; Mol.Pharmacol. 50 1495 3) Rosado and Sage (2000), Farnesylcyteine analogues inhibit store-regulated Ca2+ entry in human platelets: evidence for involvement of small GTP-binding proteins and actin cytoskeleton; Biochem.J. 347 183 4) Gordon et al. (2008), Topical N-acetyl-S-farnesyl-L-cysteine inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site; J.Invest.Dermatol. 128 643 5) Adhami et al. (2012), N-acetyl-S-farnesyl-L-cysteine suppresses chemokine production by human dermal microvascular endothelial cells Exp.Dermatol. 21 700
-20°C
TARGET: Methyltransferase -- PATHWAY: Calcium signaling; Coagulation; Posttranslational modification; Apoptosis inducer -- RESEARCH AREA: Cell death -- DISEASE AREA: Inflammation